INBRAIN Neuroelectronics, founded in 2019, is a neurotechnology company headquartered at the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Spain. It specializes in developing graphene-based brain-computer interfaces intended for neural therapies, with a focus on conditions such as Parkinson's disease, epilepsy, and stroke. The company's technical work spans graphene nanotechnology, AI-powered algorithms for data analytics, and neural decoding and modulation.
A key milestone for the company was achieving the first human implant of a graphene-based cortical interface, a device designed for decoding and modulating brain activity. Its broader end-to-end neurotechnology platform combines proprietary hardware with data analytics and AI algorithms to enable real-time precision neurology, including biomarker detection and adaptive therapeutic responses. The company has received FDA Breakthrough Device Designation for its work related to Parkinson's Disease.
The team comprises over 70 people from 20 different countries. The company was founded by researchers from the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA.
